A retrospective study from Spain assessed the relationship bet HPV infxn & biologic tx in SLE pts 🔅 Prevalence of HPV 9.9% 🔅 No significant assocs bet HPV infxn, biologic tx, SLE-related dse variables & HPV RF progression Still, emphasize HPV screening #ACR25 @RheumNow Abs0659 https://t.co/1YusM1nYPr

• https://x.com/RHEUMarampa/status/1982511293178491235/photo/1

#0777 Big news for VEXAS! 🎯 The first validated disease activity index (VEXAS-DAI) has been developed via international Delphi consensus. A 12-domain, 40-point tool to standardise assessment & power trials in this complex syndrome. Validation underway! @RheumNow #ACR25 https://t.co/DSeHb7eNeV

• https://x.com/DrMiniDey/status/1982510034925015534/photo/1

Redefining When to Biopsy the Kidney in Patients with SLE # Petri et al. ACR 2025 - Lupus nephritis may be seen in lower proteinuria too (69%) Happy to share similar results from our study-Padiyar S, As C, Gowri M, Mathew J. Lupus. 2024;33(13):1511-1517. @RheumNow

New biomarkers 14-3-3η multiplex autoantibody assay improves axSpA diagnosis, especially in HLA-B27– patients. Combined with CRP & HLA-B27, detection rose to 99% (training) & 91.4% (evaluation). In HLA-B27– cases, 14-3-3η lifted detection to 70.6% & 55%. Abstract 0531 @RheumNow

FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://t.co/Wr3tG5izCi https://t.co/P8A5PUCIX0

• FDA Approves Obinutuzumab for Active Lupus Nephritis | RheumNow

#Cancers esp #hematologic & #lung are ⬆️in Pts w #inflammatory #rheum #diseases Odds ratios of hem malignancies are wide & risk stratification is imp Are we doing a good job? 🤔skin cancer screening ??- not as per general standards Abst#0172 #ACR25 @RheumNow @ACRheum https://t.co/Uve9knXD3o

• https://x.com/Janetbirdope/status/1982506974005871012/photo/1
• https://x.com/Janetbirdope/status/1982506974005871012/photo/1

Do you believe that patients w #rheumatic #diseases flare if #extreme #weather? Even 90 days after extreme weather events flares occur - loss of power, heat’ med storage = ++stressful events Is it early flare from weather & then ++stress @RheumNow @ACRrheum #ACR25 abst#0164 https://t.co/pGPwOKrKU7

• https://x.com/Janetbirdope/status/1982506545415180367/photo/1

Why do pts with #Still’s #AOSD Get hospitalized? #Sepsis 1827 unweighted & 9135 Weighted #US #hospitalizations Worse in men Black Medicaid But is it truly #infection or Still’s flare or both? Abst#0163 ACR25 @RheumNow @rheumacr #ACRBest as largest N ever! https://t.co/fLMNyQQNNj

• https://x.com/Janetbirdope/status/1982506217764450755/photo/1

#ACR25 Beyond blinatumomab, A-319, CD3xCD19 BiTE in 12 patients with #SLE in China reported dose-dependent depth of B-Cell depletion but not efficacy or safety. One withdrew due to AE. No CRS/ICANS. Be interested to see results in larger trials & longer follow-up @RheumNow https://t.co/e5RuZlFI6i

• https://x.com/Yuz6Yusof/status/1982504797036216616/photo/1
• https://x.com/Yuz6Yusof/status/1982504797036216616/photo/1

In case there was any doubt: GCA leads to ischemic vision loss PMR does not #ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl

• https://x.com/drdavidliew/status/1982503756211310648/photo/1

Leflunomide - a perennial question in GCA, that we still haven’t answered (as this meta-analysis shows), despite clear potential. We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF? #ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg

• https://x.com/drdavidliew/status/1982502466483855856/photo/1

Even when inflammation is quiet, fatigue often lingers. In 246 RA pts, 43% had significant fatigue—closely tied to PROMs, not labs. RAPID3 < 6 flagged the few truly “fatigue-free.” Don’t overlook the VAS_Fatigue—it tells a real story. @RheumNow #ACR25 Abstract# 0380

Retrospective study by Dr. Goudot et al. - pts w/D2T PsA had dactylitis, fibromylagia & ischemic cardiomyopathy In multivariate analysis, FM & ischemic CM found to be RFs for D2T PsA ☝️Consider other dx if D2T PsA #ACR25 @RheumNow ABS0566 https://t.co/FOXv6LbysZ

• https://x.com/RHEUMarampa/status/1982501227062821053/photo/1

Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m

• https://x.com/synovialjoints/status/1982499970197414083/photo/1

After propensity matching, this retrospective cohort study showed that #lupus nephritis patients on GLP-1 agonists had ⬇️ CKD progression, mortality & AMI risk vs. LN pts on SGLT2is. Interesting data but what could explain it? Further studies are needed #ACR25 @RheumNow Abs0841 https://t.co/FtsGbMDcCv

• https://x.com/RHEUMarampa/status/1982499968767185041/photo/1